To determine if 22 could successfully treat ALS symptoms in animal models, transgenic mice carrying the human SOD1 G93A mutation were treated subcutaneously (s.c.)with 30 mg/kg 22 starting at 10 weeks of age and continuing for the lifespan of the animal. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.